OCT
01

UBT251 Injection China Phase II Clinical Study Results Presented at EASD 2026

AUG
31

The United Laboratories International Holdings Limited Announces 2026 Interim Results, Significant Progress in Innovative Drug R&D and Continued Globalization Efforts, Profit Attributable to Owners of the Company Reached Approximately RMB347.6 Million

JUN
08

Phase II Clinical Study Results of UBT251 Injection Presented at 2026 American Diabetes Association (ADA) Scientific Sessions

MAR
25

Triple Agonist UBT251 Showed a Mean HbA_1c Reduction of Up to 2.16% after 24 Weeks in Phase 2 Trial in Chinese Patients with Type 2 Diabetes

MAR
24

The United Laboratories International Holdings Limited Announces 2025 Annual Results, Achieves Significant Progress in Innovative Drug R&D, Out-licensing and Global Expansion, Profit Attributable to Owners of the Company Reaches RMB2,085.9 Million, Declares Final Dividend of RMB26 Cents per Share, with a Full-year Payout Ratio of 38%

FEB
24

Triple Agonist UBT251 Delivers up to 19.7% Mean Weight Loss after 24 Weeks in Phase 2 Trial in China